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A Claims Analysis of the Utilization of Tramadol for Acute Pain in Patients 
Prescribed Buprenorphine/Naloxone for Opioid Use Disorder 
Abstract 
Objective:  To determine the prevalence of tramadol prescribing among commercially insured 
adults receiving medication assisted therapy (MAT) with buprenorphine/naloxone.   
Design:  We conducted a cross-sectional descriptive study to evaluate the use of tramadol 
among patients prescribed buprenorphine/suboxone for MAT.  
Setting: This study utilized data from 2010 to 2013 Optum Clinformatics Data Mart 
(OptumInsight, Eden Prairie, MN).  This cohort is an administrative health claims database from 
a large national insurer. This data included pharmacy and medical care utilization and 
information describing patient enrollment. 
Patients, Participants:  Patients were 12 to 64 years of age and had complete and available 
medical, pharmacy and administrative records in the Optum Clinformatics Data Mart during 
study period. 
Main Outcome Measures:  Patients who received at least one paid claim for 
buprenorphine/naloxone from 2010 to 2013 and also received at least one overlapping 
pharmacy dispensing for tramadol were identified for analysis. We determined if the concurrent 
buprenorphine/naloxone and tramadol dispensings were from the same or a different prescriber. 
Results:  In this analysis of 18,734 U.S. commercially insured patients receiving MAT with 
buprenorphine/naloxone, we identified 1,198 (6.4%) patients who received at least one 
overlapping dispensing for tramadol during a four-year period spanning 2010 through 2013. 
Among these patients, 266 (1.42%) were co-prescribed buprenorphine/naloxone and tramadol 
from the same provider.   
Conclusions:  These results suggest that the use of tramadol among patients receiving 
buprenorphine/naloxone is not uncommon.  Further study is warranted to further determine the 
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benefits and risks associated with the use of tramadol for pain management among patients 
prescribed buprenorphine/naloxone. 
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Introduction 
Practitioners in primary care and emergency medicine frequently encounter patients with acute 
pain resulting from injuries or medical procedures. Chronic pain is also frequently encountered 
by practitioners as one of the most common reasons for an office visit, as reported by an 
estimated 20 to 50 percent of patients seen in a primary care setting.1–3 For many patients with 
opioid use disorder (OUD), medication assisted treatment (MAT) with buprenorphine-containing 
medications can be central to an effective recovery program. Consequently, there are a 
substantial and growing number of patients receiving buprenorphine/naloxone on a chronic 
basis. The clinical management of pain syndromes is a challenge among all patients, and 
particularly in the care of patients prescribed buprenorphine/naloxone for MAT.  
Opioid medications exert their analgesic effects through various receptors: mu, delta and kappa 
and other non-opioid receptors; with the most important analgesic effects mediated by mu1.4  
Buprenorphine is an opioid medication having high affinity for the mu-opioid receptors, with low 
intrinsic activity.  At dosages typically prescribed for MAT, it provides limited analgesic effect 
while blocking other opioids from binding to the mu-receptor, thereby reducing opioid craving 
and the potential for illicit opioid use.5,6  While these pharmacologic features are advantageous 
in the context of OUD, buprenorphine is not commonly utilized in the management of acute 
pain.  Furthermore, many patients with OUD suffer from chronic pain disorders.7  
Evidence-based strategies for pain management among patients receiving MAT with 
buprenorphine/naloxone are limited, presenting practitioners with a challenging clinical 
scenario.8–11  Practice guidelines issued by the American Society of Addiction Medicine (ASAM) 
for the Use of Medications in the Treatment of Addiction Involving Opioid Use consider patients 
with pain as a special population.12  These recommendations state that when medications are 
prescribed acetaminophen and NSAIDs should be considered initially, or for mild acute pain, the 
buprenorphine dosage may be increased on a temporary basis and administered in a divided 
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schedule rather than as a single daily dose. When acute pain is severe, the injectable form of 
buprenorphine may be used, or the drug may be discontinued in favor of a high potency opioid 
medication, as the strong binding of buprenorphine to mu-receptors can limit the analgesic 
effectiveness of co-administered opioid analgesic medications.13 Adding an opioid agonist while 
continuing buprenorphine/naloxone may yield a favorable response, yet there is limited 
evidence to support the safety of this approach. Discontinuing buprenorphine/naloxone and 
initiating an opioid for pain management can be problematic for patients diagnosed with OUD 
and less severe pain presentations because it simultaneously destabilizes the patient’s MAT 
while re-exposing the patient to the risks of opioid medication use.  Mixed agonist and 
antagonist analgesics, such as pentazocine, nalbuphine and butorphanol, are also best avoided 
due to the likelihood of precipitating withdrawal symptoms.14    
Tramadol was FDA-approved for marketing in the United States in March 1995 for the relief of 
moderate to severe (acute and chronic) pain in adults.15   Tramadol’s mechanism of action is 
different from traditional opioid medications.  It possesses additional (non-opioid) analgesic 
activity that is considered to be at least as strong as the opioid receptor analgesic effect of the 
drug.16  Tramadol has a relatively weak affinity for opioid receptors (mainly the mu type) and for 
neuronal reuptake of norepinephrine and 5-hydroxytryptamine (5-HT[Serotonin]) in addition to 
enhanced release of 5-HT.17,18  Tramadol exists as two enantiomers with analgesic properties 
and different analgesic mechanisms: The opioid analgesic mechanism resides primarily in the 
(+) enantiomer of the O-desmethyl (M1) metabolite of tramadol which acts as a selective mu-
receptor agonist.  The mu-receptor affinity of tramadol is 10-fold less than that of codeine, but 
the M1 metabolite has 300 times greater affinity compared to the parent compound.19 The (+)-
tramadol enantiomer also inhibits serotonin reuptake, while the (-) tramadol enantiomer inhibits 
norepinephrine reuptake; the reuptake inhibition of both of these neurotransmitters enhance 
inhibitory descending pain-modulation pathways.20  These two mechanisms act synergistically 
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to produce pain control.  Tramadol was second to hydrocodone as the most prescribed narcotic 
analgesic in the U.S. in 201621 and there is evidence that utilization has increased with the 
recent federal reclassification of hydrocodone as a schedule II drug.22  
Tramadol’s unique mechanism of action might provide utility in the management of moderate to 
severe acute pain in patients receiving MAT with buprenorphine/naloxone.  The disadvantages 
of tramadol in this setting include the risk of the patient’s misuse of an albeit weaker opioid, 
potential increased risks of adverse effects due to additive central nervous system effects in 
combination with buprenorphine, and an increased the risk of seizure. These risks are weighed 
against the risk of a potentially fatal relapse of OUD associated with the disruption of MAT with 
buprenorphine/naloxone.  
We determined the prevalence of concurrent prescribing of tramadol and 
buprenorphine/naloxone using healthcare claims data from a large national commercial insurer, 
comparing across US regions and by patient demographics.  Our findings present a basis to 
discuss the possible utility of tramadol as a therapeutic option for managing acute pain among 
patients prescribed buprenorphine/naloxone for MAT. 
 
Methods 
We conducted cross-sectional descriptive study evaluating tramadol prescription dispensings 
use among patients prescribed buprenorphine/naloxone for MAT during a four-year period 
spanning 2010 to 2013, using the Clinformatics Data Mart Database (OptumInsight, Eden 
Prairie, MN). Optum Clinformatics Data Mart is an administrative health claims database from a 
large national insurer. This data included pharmacy and medical care utilization and information 
describing patient enrollment.  
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We identified all patients having at least one paid claim for buprenorphine/naloxone during 
between January 1, 2010 and December 31, 2013 using NDC codes listed within the FDA 
directory. Patients were included in the analysis if they were 12 to 64 years of age at the time of 
paid claim during our study period. Patients age 65 years and older were excluded because 
they were substantially underrepresented in the dataset, while patients under age 12 were 
excluded as data regarding the safety and effectiveness of buprenorphine/naloxone are lacking 
in children.  We identified patients who also received at least one dispensing for concurrent use 
of tramadol, defined as having at least one day of overlap between paid prescription claims for 
each medication, as referenced by the prescriptions’ fill date and days’ supply. We also 
determined if the concurrent buprenorphine/naloxone and tramadol dispensings were from the 
same prescriber and reported these findings separately; however, information regarding 
provider specialty was unavailable.   
We determined the number and percentage of concurrent pharmacy dispensings for 
buprenorphine/naloxone and tramadol overall, and according to age, gender, and US 
geographic region, as of the first date of dispensing of buprenorphine/naloxone. For patients 
who received pharmacy dispensings for tramadol, we determined the type of pain documented 
as neuropathic, nocioceptive, inflammatory or other pain syndrome as documented within 60 
days (30 days preceding or following) of the tramadol dispensing. The statistical significance of 
differences in the frequency of current prescribing within these subgroups was determined using 
the t-test for patient age, and the chi square test for the binary and categorical variables. All 
statistical tests were two-sided and conducted at a 0.05 significance level and analyses were 
performed using SAS Enterprise Guide Version 7.1 (Cary, North Carolina, USA).  
Results 
We identified 18,734 patients who received at least one dispensing for buprenorphine/naloxone 
during 2010-2013.  The mean age of the study population was 35.47 years (SD ±11.45) and 
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approximately two-thirds of patients were male. The data source included greater patient 
representation from the US South and Midwest regions, and this was reflected in our study 
population’s demographics, as approximately 70% of patients were from these areas.  
There were 1,198 (6.39%) patients who received at least one overlapping dispensing for 
tramadol during the study period, and among these patients, 266 (1.42% of the overall study 
population) were co-prescribed buprenorphine/naloxone and tramadol from the same provider.  
These results are presented in Tables 1 and 2. Of the patients receiving overlapping 
dispensings for tramadol with buprenorphine/naloxone from differing providers, 45% (535/1198) 
were female.  A greater percentage of female patients received a concurrent tramadol 
dispensing compared male patients (8.21% versus 5.43% respectively, p < 0.0001). This trend 
was also observed for the sub-group where the prescribing was by the same provider (females: 
1.83%, male: 1.20%, P = 0.003). The mean age of patients who received tramadol dispensings 
was slightly higher than patients who did not receive tramadol dispensings (age 38.86 years 
versus 35.20 years, p < 0.001). A higher percentage of patients received tramadol dispensings 
in the south as compared with the northeast (6.92% versus 4.75% respectively, p < 0.001). 
When including the criterion that the buprenorphine/naloxone and tramadol be prescribed by the 
same provider, co-prescribing rates were lowest in the northeast (1.03%) and highest in the 
Midwest (2.01%, p = 0.003). In the majority of concurrent prescriptions (63%), tramadol 
dispensings did not have an outpatient visit within the 60-day window where a particular pain 
diagnosis was documented. Pain diagnoses documented during the medical care visit within the 
60-day window of the tramadol prescription were nocioceptive (30% of cases), neuropathic 
(2%), or inflammatory (1%); while other pain diagnoses represented 5% of total pain 
documentations.  
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Discussion 
Our findings indicate that the concurrent use of buprenorphine/naloxone and tramadol is 
occurring in clinical practice, as 6.4% of all patients utilizing buprenorphine/naloxone had at 
least 1 overlapping prescription for tramadol during the study timeframe.  This finding is 
consistent with other research indicating that patients prescribed buprenorphine/naloxone often 
continue to receive prescriptions for other opioid medications. For example, an analysis of 
patients initiating buprenorphine across 11 states (n = 38,096) found that 43.2% of patients 
received at least one dispensing for another opioid medication during the treatment episode.23  
Another study examining pharmacy records within Pennsylvania Medicaid during 2007 to 2012 
found that 34.7% of patients prescribed buprenorphine also received dispensings for other 
opioids.24  While these studies included tramadol in the categorization of other opioids, they did 
not specifically report rates of co-prescribing with tramadol.  
In our study, it is possible that a substantial number of the tramadol prescriptions were issued 
by prescribers who were unaware that the patient was also utilizing buprenorphine/naloxone. 
Our study timeframe precedes the widespread implementation of state prescription drug 
monitoring programs, which provide prescribers with details of patients’ controlled substance 
utilization.  We consider it to be likely that many tramadol prescribers in our study were unaware 
that the patient was also utilizing buprenorphine/naloxone, yet also that others prescribed the 
combination intentionally.   As a sub-analysis, we examined overlapping use of 
buprenorphine/naloxone and tramadol when prescribed from the same provider. We identified 
266 such instances, representing 1.42% of all patients utilizing buprenorphine/naloxone during 
our study period.  This suggests that for these cases some providers considered tramadol to be 
an acceptable option for treating pain when patients were also utilizing buprenorphine/naloxone, 
although perhaps they were unaware of the nature of the risks of co-prescribing these 
medications.   
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The use of tramadol is discouraged among patients prescribed buprenorphine/naloxone.  The 
product labeling includes a black box warning that tramadol should not be prescribed 
concomitantly with other central nervous system (CNS) depressants, as the combination 
increases risk of respiratory depression and death.25  Yet the labeling also notes that for such 
patients, tramadol should be reserved for patients lacking adequate treatment alternatives, and 
when prescribed, patients should be monitored for sedation and respiratory depression; 
however, such monitoring is likely not practical in the outpatient setting. Additionally, the labeling 
notes that mixed agonist/antagonist and partial agonist opioids (e.g. buprenorphine) may 
diminish the effectiveness of tramadol, and states that the concomitant use of these medications 
should be avoided.   
Prescribers should also be aware of genetic polymorphisms causing variation in tramadol 
metabolism via cytochrome P450 isoenzymes 2D6, 2B6 and 3A4, with CYP2D6 being integral 
in converting tramadol to its more potent M1 metabolite.26  Ultra-rapid metabolizers may 
produce greater levels of this active metabolite and be at a greater risk of experiencing CNS 
depression with tramadol use, particularly when taken concurrently with buprenorphine.27,28  
Ethiopians and Saudi Arabians are more likely to be rapid metabolizers (10-26%), followed by 
Caucasians (5-10%), and less commonly African Americans (2-3%), Indians (3.5%), Hispanics 
and Asians (approximately 1% within each group).  In contrast, poor metabolizers (up to 10% of 
European Caucasians) may fail to experience pain relief. Genetic testing or pharmacogenomic 
analysis is becoming available that would allow for the identification of polymorphisms in 
individual patient CYP 2D6 enzymes that could alter tramadol metabolism.31,32  Patients 
receiving MAT therapy for their OUD who are also receiving treatment with tramadol for acute 
pain would be ideal candidates for these pharmacogenomic tests. Strong CYP2D6 inhibitors 
such as amitriptyline, bupropion, duloxetine, fluoxetine and paroxetine will likely diminish 
tramadol’s effectiveness as an analgesic.32  Other important risks of tramadol that prescribers 
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must consider include an enhanced seizure risk,25 its potential teratogenicity, and at least 
theoretically, the risk of serotonin syndrome among patients prescribed multiple serotonergic 
medications. 33,34 
Counterbalancing these important risks is the need for effective options for managing acute pain 
among patients with OUD without disrupting a successful MAT modality and placing the patient 
at risk for relapse and overdose death.  There are an increasing number of patients utilizing 
MAT who require buprenorphine for treatment of their OUD and these patients can be expected 
to suffer acute and chronic pain, perhaps more often than the general population. There is a 
dearth of evidence to guide and inform practice.  Tramadol’s unique pharmacology involving 
both opioid-receptor and serotonergic action provides a theoretical mechanism for effective 
analgesic effect when used concomitantly with buprenorphine. The data we analyzed suggest 
that tramadol and buprenorphine/naloxone are being used concurrently in community practice, 
albeit by a relatively small number of patients. Tramadol may have a role in the treatment of 
acute and chronic pain in selected patients receiving buprenorphine/naloxone, necessitating 
further study of its associated risks and health outcomes.  
Our study had several limitations. First, our study utilized administrative claims data describing 
medications dispensed from retail pharmacies. We were unable to determine if patients actually 
consumed the medications, or to what extent patients were adherent to buprenorphine or 
tramadol. Patients may have also been instructed to temporarily discontinue 
buprenorphine/naloxone while using tramadol. Also, our results were derived from a US 
commercially insured population, and should not be generalized to other populations including 
Medicaid or Medicare. Additionally, in recent years most states have implemented Prescription 
Drug Monitoring Programs, which alert prescribers to the patient’s use of controlled substances 
prescribed by other practitioners. Our results precede the widespread implementation of these 
programs. Our use of a cross-sectional study design also includes limitations, as our analyses 
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are associations which are subject to selection bias, confounding, and measurement error, 
therefore, the findings in this study are hypothesis generating to inform the development and 
implementation of future studies.  Additionally, we did not examine the use of tapentadol, 
butorphanol or injectable buprenorphine as alternatives for acute pain, deciding instead to focus 
on tramadol, which is available in a low cost generic form and is generally accessible without 
barriers under typical pharmacy insurance plan designs.   Finally, we were unable to fully 
describe the pain syndromes experienced by the patients because characteristics such as the 
history and degree of pain are difficult to ascertain using secondary data sources.  
Conclusions 
In this analysis of 18,734 US commercially insured patients receiving buprenorphine/naloxone, 
we identified 1,198 (6.4%) patients who received at least one overlapping dispensing for 
tramadol, and 266 patients (1.42%) who were co-prescribed buprenorphine/naloxone and 
tramadol from the same provider.  These results suggest that the use of tramadol in this 
population is not uncommon. Further study is warranted to determine the potential utility of 
tramadol for pain management among patients prescribed buprenorphine/naloxone. 
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Table 1. Use of Tramadol among 18,734 Commercially-Insured Patients Receiving 
Dispensings for Buprenorphine/Naloxone in 2010-2013  
 
Characteristic 
Patients receiving 
buprenorphine/naloxone 
and no concurrent use of 
tramadol 
Patients with at least 1 
instance of concurrent use of 
buprenorphine/naloxone and 
tramadol 
p-value 
       
Overall, N (%) 17,536 (94%) 1,198 (6.39)  n/a 
       
Patient Age, Years,        
    Mean (SD) 35.20  (11.4) 38.86 (11.3)  < 0.001 
       
Gender, N (%)       
   Female 5,983 (91.79) 535 (8.21)  <0.001 
   Male 11553 (94.57) 663 (5.43)   
       
U.S. Region, N (%)       
   Northeast 2,507 (95.25) 125 (4.75)  <0.001 
   Midwest 3,427 (93.12) 253 (6.88)   
   South 8,974 (93.08) 667 (6.92)   
   West 2,622 (94.49) 153 (5.51)   
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Table 2. Use of Tramadol among 18,734 Commercially-Insured Patients Receiving 
Dispensings for Buprenorphine/Naloxone in 2010-2013 where both Medications were 
Issued by the Same Prescriber  
 
Characteristic 
Patients receiving 
buprenorphine/naloxone 
and no concurrent use of 
tramadol from the same 
prescriber 
Patients with at least 1 instance 
of concurrent use of 
buprenorphine/naloxone and 
tramadol from the same 
prescriber 
p-value 
       
Overall, N (%) 18,468 (99%) 266 (1.42)  n/a 
       
Patient Age, 
Years,  
  
    
    Mean (SD) 35.41  (11.4) 40.51 (11.2)  < 0.001 
       
Gender, N (%)       
   Female 6399 (98.17) 119 (1.83)  0.003 
   Male 12069 (98.80) 147 (1.20)   
       
U.S. Region, N (%)       
   Northeast 2605 (98.97) 27 (1.03)   0.003 
   Midwest 3606 (97.99) 74 (2.01)   
   South 9518 (98.72) 123 (1.28)   
   West 2733 (98.49) 42 (1.51)   
 
 
